Literature DB >> 31237799

T cells producing GM-CSF and IL-13 are enriched in the cerebrospinal fluid of relapsing MS patients.

Laura Ghezzi1, Claudia Cantoni2, Francesca Cignarella2, Bryan Bollman2, Anne H Cross3, Amber Salter4, Daniela Galimberti5, Marina Cella6, Laura Piccio7.   

Abstract

BACKGROUND: Multiple sclerosis (MS) is a central nervous system (CNS) autoimmune demyelinating disease. Its pathogenesis involves humoral and cellular immunity, with production of pro- and anti-inflammatory cytokines by T cells.
OBJECTIVE: To analyze the cytokine profile of cerebrospinal fluid (CSF) T cells in patients with relapsing-remitting MS (RRMS) and non-inflammatory controls.
METHODS: T cell cytokine production was analyzed by flow cytometry in CSF samples collected from 34 untreated RRMS patients and 20 age-matched controls. Immunofluorescence studies were performed in spinal cord MS active lesions.
RESULTS: Percentages of CSF-derived IL-17A, IL-17A/IL-22, and IL-17A/GM-CSF producing T cells were significantly higher in RRMS patients compared to controls. Percentages of T cells producing IFN-γ were lower in RRMS patients compared to controls. Patients in relapse showed higher percentages of CD4+ T cells producing IL-13 and GM-CSF compared to patients in remission. We found a positive correlation between percentages of IL-13+ T cells and the Expanded Disability Status Scale (EDSS; ρ = 0.5; p < 0.05). Meningeal IL-13-producing T cells were detected in spinal cord MS active lesions.
CONCLUSION: We observed differences in IL-17, IL-22, and IFN-γ production by CSF T cells in RRMS versus controls and a positive correlation between IL-13-producing T cells and EDSS in RRMS patients.

Entities:  

Keywords:  Multiple sclerosis; T cells; cerebrospinal fluid; cytokines

Year:  2019        PMID: 31237799     DOI: 10.1177/1352458519852092

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  8 in total

Review 1.  Neuroinflammation: Extinguishing a blaze of T cells.

Authors:  Nail Benallegue; Hania Kebir; Jorge I Alvarez
Journal:  Immunol Rev       Date:  2022-07-31       Impact factor: 10.983

Review 2.  Intranasal Delivery: Effects on the Neuroimmune Axes and Treatment of Neuroinflammation.

Authors:  Elizabeth M Rhea; Aric F Logsdon; William A Banks; Michelle E Erickson
Journal:  Pharmaceutics       Date:  2020-11-20       Impact factor: 6.321

3.  Sample Size for Oxidative Stress and Inflammation When Treating Multiple Sclerosis with Interferon-β1a and Coenzyme Q10.

Authors:  Marcello Moccia; Antonio Capacchione; Roberta Lanzillo; Fortunata Carbone; Teresa Micillo; Giuseppe Matarese; Raffaele Palladino; Vincenzo Brescia Morra
Journal:  Brain Sci       Date:  2019-09-27

4.  Pathogenic T cell cytokines in multiple sclerosis.

Authors:  Catriona A Wagner; Pamela J Roqué; Joan M Goverman
Journal:  J Exp Med       Date:  2020-01-06       Impact factor: 14.307

Review 5.  T Helper Cells: The Modulators of Inflammation in Multiple Sclerosis.

Authors:  Martina Kunkl; Simone Frascolla; Carola Amormino; Elisabetta Volpe; Loretta Tuosto
Journal:  Cells       Date:  2020-02-19       Impact factor: 6.600

6.  Melanoma Cell Adhesion Molecule Expressing Helper T Cells in CNS Inflammatory Demyelinating Diseases.

Authors:  Ryotaro Ikeguchi; Yuko Shimizu; Akihiro Kondo; Natsuki Kanda; Hayato So; Haruka Kojima; Kazuo Kitagawa
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-24

7.  Brain Antigens Stimulate Proliferation of T Lymphocytes With a Pathogenic Phenotype in Multiple Sclerosis Patients.

Authors:  Assaf Gottlieb; Hoai Phuong T Pham; John William Lindsey
Journal:  Front Immunol       Date:  2022-01-31       Impact factor: 7.561

Review 8.  Interrelationship and Sequencing of Interleukins4, 13, 31, and 33 - An Integrated Systematic Review: Dermatological and Multidisciplinary Perspectives.

Authors:  Alin Laurentiu Tatu; Anca Arbune; Valentin Chioncel; Elena Niculet; Thomas Nadasdy; Carmen Bobeica; Alina Viorica Iancu; Caterina Dumitru; Valentin Tudor Popa; Nicolas Kluger; Victor Gabriel Clatici; Claudiu Ionut Vasile; Cristian Onisor; Alexandru Nechifor
Journal:  J Inflamm Res       Date:  2022-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.